RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Cost-effectiveness of cabotegravir long-acting for pre-exposure prophylaxis versus current use of daily oral tenofovir disoproxil fumarate/emtricitabine or no prep to prevent HIV-1 in individuals at high risk in Spain.
Neches, V., Campbell, K., Coll, P., Moreno Guillen, S., Martinez-Sesmero, JM., Lopez Segui, F., O'Brien, P., Davis, A. E., Anderson, SJ., Schroeder , M., & Vallejo-Aparicio, LA. (2024). Cost-effectiveness of cabotegravir long-acting for pre-exposure prophylaxis versus current use of daily oral tenofovir disoproxil fumarate/emtricitabine or no prep to prevent HIV-1 in individuals at high risk in Spain.Value in Health, 27(6).
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.